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AbstrACt
Objectives To evaluate the impact of palliative home care 
support on the quality of care and costs in the last 14 days 
of life.
Design Matched cohort study using linked administrative 
databases.
setting All people who died in Belgium in 2012 
(n=107 847).
Participants 8837 people who received palliative home 
care support in the last 720 to 15 days of life matched 1:1 
by propensity score to 8837 people who received usual 
care.
Intervention Receiving the allowance for palliative 
home patients, multidisciplinary palliative home care 
team visit or palliative nurse or physiotherapist visit at 
home.
Main outcome measures Home death, number of family 
physician contacts, number of primary caregiver contacts, 
hospital death, hospital admission, intensive care unit 
(ICU) admission, emergency department (ED) admission, 
diagnostic testing, blood transfusion and surgery. Total 
inpatient and outpatient costs. All outcomes were 
measured in the last 14 days of life.
results In the unmatched cohort, 11 149 (13.5%) people 
received palliative home care support in the last 720 to 15 
days of life. After matching, those using palliative home 
care support had, compared with those who did not, more 
family physician contacts (mean 3.1 [SD=6.5] vs 0.8 
[SD=1.2]), more chance of home death (56.2%vs13.8%; 
relative risk [RR]=4.08, 95% CI 3.86 to 4.31), lower risk of 
hospital admission (27.4%vs60.8%; RR=0.45, 95% CI 0.43 
to 0.46), ICU admission (18.3%vs40.4%; RR=0.45, 95% CI 
0.43 to 0.48) or ED admission (15.2%vs28.1%; RR=0.54, 
95% CI 0.51 to 0.57). Mean total costs of care were lower 
for those using palliative home care support (€3081 
[95% CI €3025 to €3136] vs €4698 [95% CI €4610 to 
€4787]; incremental cost: −€1617 [p<0.001]).
Conclusions Palliative home care support use positively 
impacts quality of care and reduces total costs of care at 
the end of life in Belgium. Policy makers and healthcare 
practitioners should increasingly focus on communicating 
the existing options for palliative home care support to 
patients and their caregivers.
bACkgrOunD 
A majority of the growing population encoun-
tered with chronic and life-limiting illnesses 
prefers to receive high-quality care and to 
die at home.1 2 Palliative home care support 
aims to meet the needs of these people by 
managing symptoms, improving quality of 
life and preventing avoidable healthcare 
interventions such as hospitalisations at the 
end of life.3 It is estimated that palliative care 
could be beneficial in 38%–74% of all deaths 
worldwide.4 In recent years, policy makers 
internationally have focused on promoting 
the integration of palliative care services into 
the community and on developing supportive 
strengths and limitations of this study
 ► By using nationwide administrative data on every 
death over one whole year, our findings are gener-
alisable to the full population, whereas experimen-
tal studies, surveys or sample-based observational 
studies often have difficulties in reaching certain 
under-represented subgroups and lack the strength 
necessary for generalisability.
 ► A matched cohort study design with a high-quality 
matching is the best possible technique to evaluate 
the impact of policy on quality and costs of care, giv-
en ethical and practical concerns.
 ► No previous work has evaluated the impact of all 
palliative home care support available in one coun-
try for the full population.
 ► Our operationalisation of palliative home care sup-
port as the use of any of available policy measure 
increases the reproducibility of our study in other 
countries and allows comparison studies that focus 
on the impact of other existing types of palliative 
home care support, especially in countries with sim-
ilar health care service delivery models and funding.
 ► Important aspects of quality end-of-life care are 
not visible in administrative data, such as quality of 
communication, existential or psychological care. 
Qualitative research can complement our findings.
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policy measures for palliative care at home to meet the 
growing demand for high-quality home-based palliative 
care and to reduce costs related to acute hospital care 
use at the end of life.5–7 Several countries offer palliative 
home care support in the form of multidisciplinary palli-
ative home care teams, palliative nursing care at home or 
financial support for those wanting to receive palliative 
care at home.8–11
The impact of using palliative home care support on 
the quality and costs of care at the end of life remains 
poorly evaluated.12 A Cochrane review that included 23 
studies found that use of home palliative care services 
more than doubled the odds of dying at home and 
reduced symptom burdens.13 Six studies focused on 
costs and reported up to 35% lower costs in the inter-
vention group compared with a control group. Only one 
study reported statistically significant differences, but the 
authors pointed out that ‘the existence of economically 
significant differences [in the other studies] cannot be 
ruled out due to small sample sizes unlikely to have suffi-
cient power to detect statistical significance’. Another 
recently updated Cochrane review included four trial 
studies that evaluated ‘hospital at home’ services, demon-
strating the positive impact of this type of home-based 
end-of-life care on the chances of having a home death, 
but results on hospital admissions and healthcare costs 
varied and were found inconclusive.14
However, traditional experimental study designs, such 
as those evaluated in the above-mentioned reviews, are 
limited due to ethical and practical concerns (eg, it would 
be illegal to refrain patients from receiving any palliative 
home care in a trial). Therefore, they are not suitable 
for evaluating the impact of palliative home care support 
that are available nationally to everyone across a health-
care system.3 A matched cohort study design with a high-
quality matching on the propensity of receiving palliative 
home care is the best possible technique to evaluate this 
impact.15 The increasing availability and improving quality 
of routinely-collected databases and the technical possibil-
ities of linking data from various sources have opened up 
new possibilities for such designs.16 Three retrospective 
cohort studies using matched controls found an impact 
of palliative home care support on reducing hospitalisa-
tions at the end of life and on lower chances for hospital 
deaths in Canada, England and the USA.17–20 Findings 
from another retrospective cohort study suggested that a 
proactive home-based palliative care programme ‘helped 
to avoid the escalation in hospital use and costs commonly 
seen in the final months of life’.21 However, these studies 
focused only on a limited number of outcomes as indica-
tors of quality of end-of-life care (hospital use and place 
of death) and only one focused additionally on costs, 
without distinguishing inpatient and outpatient costs. 
None of the studies used population-level national data, 
therefore limiting the findings to one specific province 
or region.
In Belgium, palliative home care support is available in 
the form of: (1) a multidisciplinary palliative home care 
team, (2) palliative home care nursing or physiotherapy 
and (3) the allowance for palliative home care patients, 
available twice and meant for non-reimbursed palliative 
care-related costs. These supportive policy measures are 
entirely free to the patient and their informal caregivers. 
Using linked register-based databases on all deaths in 
Belgium, the current study aims to evaluate the impact 
of using palliative home care support on the appropri-




We conducted a matched cohort study on all deaths in 
Belgium in 2012, using linked data from eight admin-
istrative databases. An individual that used at least one 
type of palliative home care support was matched to an 
individual that used no palliative home care support. To 
reduce selection bias between the groups and to balance 
measured covariates across them, we used propen-
sity score matching.15 We followed an extension of the 
Strengthening the Reporting of Observational Studies 
in Epidemiology guidelines for reporting observational 
studies to report the propensity score matching analysis.16 
study setting and participants
The study was conducted for all those who were regis-
tered with a Belgian sickness fund at time of death in 
2012 (98.8% of all deaths). We excluded people younger 
than 18 years and those who had permanent residence 
in a nursing home during the last year of life. Addition-
ally, to avoid any overlap between the timing of exposure 
and the timing of the outcomes, we excluded those for 
whom palliative home care support was initiated for the 
first time in the last 14 days of life. Figure 1 presents the 
study population selection process.
The data used involved eight administrative databases, 
linked on an individual level using a unique identifier by 
a third party responsible for data protection and linkage 
in Belgium. The linked data included person-level reim-
bursed healthcare use in the last 2 years of life (recorded 
as nomenclature codes) including dispensed medication 
in the hospital and community pharmacy in the last 2 years 
of life (recorded as Anatomical Therapeutic Chemical 
Classification System (ATC) codes). For all healthcare 
data, the exact date of delivery (coded as number of days 
before death) is recorded. Additionally, the data include 
demographic data, fiscal data (ie, net taxable annual 
income) and death certificate data (including underlying 
cause of death, coded using International Statistical Clas-
sification of Diseases, Tenth Revision (ICD-10) codifica-
tion).22 The data linkage process and content is described 
in detail elsewhere.23
Patient and public involvement
We used previously validated quality indicators (QIs) 
for end-of-life care to measure appropriateness and 
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inappropriateness of end-of-life care on an aggregated 
level. Patients were not directly involved in the design of 
the study or development of the QIs. The design of the 
study, using population-level decedent data, did not allow 
to disseminate results to or involve observed patients in 
the development of the research questions or outcome 
measures.
exposure group
Our exposure group consisted of people who used at 
least one type of palliative home care support between 
the last 720 and 15 days of life (see box 1). We included 
all persons receiving palliative home care support for the 
longest time frame available in our data, that is, up to 720 
days before death. We did not want to exclude persons on 
the basis of a (retrospectively) predefined time frame, as 
this information (time before death) would not be known 
using a prospective design. The inclusion criteria were: 
(combined by ‘OR’): (1) having received the allowance 
for palliative home patients, (2) having a visit by a multi-
disciplinary palliative home care team visit or (3) having 
a visit by a palliative nurse or physiotherapist at home. 
Using specific nomenclature codes, we could identify 
delivery, health insurance-reimbursed cost and timing 
of a specific palliative home care support. The data were 
sorted to identify the earliest use of palliative home care 
support when multiple measures were used.
The Belgian health system is primarily funded through 
social security contributions and taxation, with a compul-
sory national health insurance, which covers the whole 
population. Compulsory health insurance is combined 
with a private system of healthcare delivery, based on 
independent medical practice, free choice of service 
provider and predominantly fee-for-service payment. It 
is important to note that all healthcare insured people 
in Belgium have the legal right to access palliative home 
care support. Family physicians play a gatekeeping role 
in this: they remain responsible for all care provided at 
home and need to give their written permission to initiate 
any of the palliative home care support. Receiving any of 
these was chosen as exposure because we considered the 
different types of support to be an indication of the same 
intervention: initiation of palliative home care. However, 
sensitivity analyses were performed in which each sepa-
rate support type is selected as the basis for the exposure 
group.
non-exposure group
People who did not use palliative home care support in 
the last 2 years of life were included in the non-exposure 
group.
Outcomes for appropriateness and inappropriateness of end-
of-life care
We used QIs for appropriate and inappropriate end-of-
life care that were developed using the RAND/UCLA 
Appropriateness method that aims ‘to combine the best 
available scientific evidence with the collective judgment 
of experts to yield a statement regarding the appropriate-
ness of performing a procedure at the level of patient-spe-
cific symptoms, medical history, and test results’.24 We 
included the following indicators for appropriateness of 
Figure 1 Flow chart of the study population selection.
box 1 Description of the exposure: palliative home care 
support in belgium
Policy measures to support palliative care at home, here defined as 
‘palliative home care support’, exist in Belgium since 1985.30 In 2002, 
palliative care was recognised by Belgian law as a right for all Belgian 
citizens. Since then, seriously ill patients with a short life expectancy 
(defined by law as ‘more than 24 hours and less than three months’) and 
an intention to die at home are eligible to receive specific supportive 
measures from the Belgian government.32 These are:
a. The use of a multidisciplinary palliative home care team: which in-
cludes at least one general practitioner, two nurses and an admin-
istrative assistant. The main goal of the multidisciplinary palliative 
home care teams is to advise family physicians, health profession-
als, counsellors, informal carers and volunteers involved in the 
provision of palliative home care of a patient and to organise and 
coordinate the provision of that palliative care at home between dif-
ferent care providers. The use of these teams is free of charge for 
the patient and not limited in time.
b. Palliative home care nursing or physiotherapy: type of nursing care 
or physiotherapy at home, differing from standard nursing care or 
physiotherapy at home for heavily dependent home-patients in the 
number of caring tasks provided and round-the-clock availability. 
Free of charge for the patient.
c. The allowance for palliative home patients: a lump sum of €647.16 
(in 2012), which is obtainable twice (possibility to claim a second 
after 1 month) and meant to cover for non-reimbursed or partially 
reimbursed costs that are related to the provision of palliative care 
at home (eg, certain medicines, care materials and tools).
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end-of-life care, all pertaining to the last 14 days of life: 
dying at home; the average number of primary care-
giver contacts; and the average number of family physi-
cian contacts. We included the following indicators for 
inappropriateness of end-of-life care: dying in a hospital; 
being admitted to hospital; being admitted to an emer-
gency department (ED); being admitted to an intensive 
care unit (ICU); being submitted to diagnostic testing (ie, 
medical imaging, ECG or pulmonary function testing); 
having a blood transfusion; and having surgery.
The QIs measure the prevalence of specific medication 
types (recorded in the data sources using ATC codes) or 
healthcare interventions (recorded in the data sources as 
nomenclature codes for reimbursement purposes) within 
a specified period before death. For example, the QI 
‘average number of primary caregiver contacts in the last 
fourteen days of life’ is calculated as the mean number 
of contacts with a family physician or other primary care 
professional (based on the number of relevant registered 
nomenclature codes) in the last 14 days of life. The devel-
opment, validation process and use of these indicators to 
study end-of-life care on a population level is described in 
detail in De Schreye et al.25
Costs of end of life
Based on all specific healthcare consumption data, we 
calculated total healthcare costs from a third-party and 
patient copayment perspective, consisting of total inpa-
tient cost and total outpatient cost for both groups. 
Inpatient costs included all specific intervention and 
medication costs in the hospital. Outpatient costs included 
all specific intervention and medication costs outside the 
hospital. For a detailed description, see online supple-
mentary box 1. Based on the exact dates of delivery we 
calculated the total costs for the last 14 days of life. All 
costs were actualised to 2017 values based on the unit cost 
of all defined resources in that year.
Propensity score matching and statistical analysis
Descriptive statistics were used to describe population 
characteristics, stratified by having received palliative 
home care support (exposure group) or not (non-expo-
sure group).
People who received palliative home care support were 
matched to those who did not, based on an individual esti-
mation of their propensity for receiving palliative home 
care support. To calculate the propensity scores, relevant 
predictors for receiving palliative home care, based on 
previous research findings, were used as baseline covari-
ates.13 The following baseline covariates were used: age at 
death, sex, underlying cause of death (as a proxy for diag-
nosis using ICD-10 codification, these were recoded into: 
neoplasms [C00-D48], respiratory diseases [J40-44 and 
J47], other organ failures, ie, heart, renal and liver failure 
[I11-I13, I50, K70-72, N10-12 and N18-19], neurodegener-
ative diseases, ie, Alzheimer’s disease, Parkinson’s disease, 
motor neuron and Huntington’s disease [F01, F03, 
G10, G12, G20 and G30], HIV/AIDS [B20-24]; other 
underlying causes of death were recoded as ‘other’), 
household type, personal annual taxable income, highest 
attained educational level, degree of urbanisation of 
residence, region of residence and hospital use in the 
last 2 years of life (based on the criteria: ‘having had at 
least six hospitalisations’ and ‘being at least 120 days in 
the hospital’). We used a greedy one to one case–control 
propensity score matching algorithm.26 For every case, 
the best match was made first and a next-best match next, 
in a hierarchical sequence until no more matches could 
be made. Best matches are those with the highest digit 
match on propensity score. First, cases are matched to 
controls on eight digits of the propensity score. For those 
that do not match, cases are then matched to controls on 
seven digits of the propensity score and so on. The algo-
rithm proceeds sequentially to the lowest digit match on 
the propensity score (one digit). In view of performing 
sensitivity analyses, we performed separate matchings 
with, respectively, allowance for palliative home care 
patients, multidisciplinary palliative home care team visit 
and palliative nursing care or physiotherapy at home on 
its own as exposure, to evaluate whether these types of 
support showed different results.
Two sampled t-test statistics were used to test for signif-
icant differences in age, and χ2 statistics were used to test 
for significant differences in dichotomous and categor-
ical variables describing the unmatched and matched 
exposed and non-exposed groups. Risk ratios were calcu-
lated to measure the differences in outcomes between the 
exposed group and the non-exposed group. Costs were 
presented as means, medians, SEs and IQRs. All analyses 
were performed using SAS Enterprise Guide V.7.1.
results
study population characteristics
Of all deaths in Belgium in 2012 (n=107 847), we 
excluded 25 226 individuals from our study population 
because they resided in a nursing home (18.9% of total 
population), were minors (0.4%) or used palliative home 
care support only during the last 14 days of life (4.5%) 
(figure 1). Our final unmatched set consisted of 82 621 
individuals of which 11 149 (13.5%) had initiated palli-
ative home care support in the last 720–15 days of life 
(table 1). Before matching, the sociodemographic char-
acteristics of the cohort exposed to palliative home care 
support differed largely from the unexposed cohort (eg, 
in cause of death, household composition and hospital 
use during the last 2 years of life). After propensity score 
matching, 8837 exposed people were matched to as many 
unexposed people. We performed sensitivity analyses on 
each support type separately with no substantial differ-
ences in the impact on the QI outcomes (online supple-
mentary table 1).
Indicators of appropriate end-of-life care
Fifty-six per cent of the people using palliative home care 
support died at home, compared with 13.8% of those who 
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Table 1 Characteristics of people using palliative home care support (exposed) and people who did not use palliative home 
care support (unexposed) before and after propensity score matching
Characteristics
Before propensity score matching (n=82 621) After propensity score matching (n=17 674)
Exposed Unexposed Exposed Unexposed
No. of patients (%) 11 149 (13.5) 71 472 (86.5) 8837 (50) 8837 (50)
Earliest use of palliative home care in days, 
median (IQR)
75 (154)    / 73 (152)    /
Mean age at time of death (SD) 74.2 (12.8) 76.5 (14.2) 74.4 (12.7) 75.0 (12.3)
Sex
  Men 55.2 54.6 56.0 55.1
  Women 44.8 45.4 44.0 44.9
Cause of death
  Neoplasm 74.6 20.6 72.7 72.8
  COPD 2.5 4.6 2.7 2.8
  Other organ failure 3.2 5.9 3.5 3.1
  Neurodegenerative 4.4 5.0 4.9 5.1
  Other 15.3 63.8 16.2 16.3
Household composition
  Married 60.4 44.6 60.4 61.4
  Single-person household 26.2 41.5 26.7 26.4
  Living together 4.1 4.2 4.0 3.6
  One-parent family 6.4 6.7 6.2 5.9
  Other 2.9 3.0 2.7 2.7
Education level
  No education 8.1 8.7 7.9 7.7
  Primary school education 34.7 34.9 34.7 35.2
  Secondary school education 44.8 45.2 45.0 44.6
  Postsecondary school education 12.5 11.2 12.4 12.6
Income in quartiles*
  Lowest income quartile 29.2 26.2 28.4 28.7
  Second income quartile 22.5 23.5 21.7 21.9
  Third income quartile 24.1 24.5 24.3 24.8
  Highest income quartile 24.3 25.9 25.6 24.6
Region
  Flemish region 66.4 53.1 65.4 64.5
  Walloon region 28.8 36.8 29.6 30.4
  Brussels capital region 4.8 10.1 5.0 5.1
  Urbanisation
  Very high 25.1 33.7 25.7 25.6
  High 28.5 27.5 29.2 28.7
  Average 32.0 24.4 30.7 30.6
  Low 12.9 13.0 13.0 13.7
  Rural 1.5 1.5 1.5 1.5
Hospital use in the last 2 years
  ≥120 days hospitalised 4.7 5.3 4.6 4.0
  ≥6 hospitalisations 46.5 14.7 44.5 44.6
Values are percentages of patients unless stated otherwise. All percentages are valid percentages. Missing values existed in the full 
population (n=107 847) for household composition (n=1399; 1.6%), education level (n=11 382; 13.1%), income (n=3563; 4.1%), region (1657; 
1.9%), urbanisation (1657; 1.9%).
*Income quartiles were calculated on the full population of decedents (n=107 847).
COPD, chronic obstructive pulmonary disease.
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did not use palliative home care support (relative risk 
[RR]=4.08; 95% CI 3.86 to 4.31 (table 2). On average, 
people in the palliative home care support cohort had 
nine primary caregiver contacts and three family physi-
cian contacts in the last 2 weeks of life, compared with 
two primary caregiver contacts and less than one family 
physician contact for those in the unexposed cohort.
Indicators of inappropriate end-of-life care
Thirty-nine per cent of the people using palliative home 
care support died in the hospital, compared with 74.8% 
of the people not using palliative home care support 
(RR=0.52; 95% CI 0.51 to 0.54). Less people in the pallia-
tive home care support cohort were admitted to a hospital 
(27.4% vs 60.8%; RR=0.45, 95% CI 0.43 to 0.46), to an 
intensive care unit (18.3% vs 40.4%; RR=0.45, 95% CI 
0.43 to 0.48) or to an ED (15.2% vs 28.1%; RR=0.54, 
95% CI 0.51 to 0.57) in the last 2 weeks of life. Less people 
who used palliative home care support were submitted 
to diagnostic testing (27.2% vs 63.2%; RR=0.43, 95% CI 
0.41 to 0.45), received blood transfusion (2.7% vs 5.9%; 
RR=0.47, 95% CI 0.40 to 0.54) or surgery (0.5% vs 2.8%; 
RR=0.19, 95% CI 0.14 to 0.26) (table 2).
Medical care costs
Mean total inpatient costs were lower for people using palli-
ative home care support (€1766; 95% CI €1706 to €1826) 
compared with those who did not use palliative home 
care support (€4222; 95% CI €4133 to €4311) (p<0.001) 
(table 3). Mean total outpatient costs were higher for 
people using palliative home care support (€1314; 
95% CI €1291 to €1337) compared with those who did 
not (€476; 95% CI €461 to €492) (p<0.001). Mean 
incremental total costs for exposed versus unexposed 
people in the last 2 weeks of life was −€1617 (SE=53.2). 
We performed sensitivity analyses on each support type 
separately with no substantial differences in the impact 
on the costs of care at the end of life (online supplemen-
tary table 2).
DIsCussIOn
To our knowledge, this is the first nationwide matched 
cohort study on the impact of palliative home care 
support on the quality and costs of care at the end of life, 
using validated QIs. We found that people using palliative 
Table 2 Indicators of appropriate and inappropriate end-of-life care in the last 14 days of life in the matched cohorts
Palliative home care support (n=17 674)
RR (95% CI)Yes (n=8837) No (n=8837)
Indicators of appropriate end-of-life care
Home death 56.2 13.8 4.08 (3.86 to 4.31)
Mean number of family physician contacts (SD)* 3.1 (3.0) 0.8 (1.2) /
Mean number of primary caregiver contacts (SD)* 9.0 (6.2) 2.3 (4.0) /
Indicators of inappropriate end-of-life care
Hospital death 39.0 74.8 0.52 (0.51 to 0.54)
Hospital admission 27.4 60.8 0.45 (0.43 to 0.47)
ICU admission 18.3 40.4 0.45 (0.43 to 0.48)
ED admission 15.2 28.1 0.54 (0.51 to 0.57)
Diagnostic testing 27.2 63.2 0.43 (0.41 to 0.45)
Blood transfusion 2.7 5.9 0.47 (0.40 to 0.54)
Surgery 0.5 2.8 0.19 (0.14 to 0.26)
*P<0.0001 calculated using two-sided t-test statistic. 
 ED, emergency department; ICU, intensive care unit; RR, relative risk. 
Table 3 Healthcare costs in the last 14 days of life in the matched cohorts (in euro)
Palliative home care support (n=17 674)
Mean incremental
(P value)
Yes (n=8837) No (n=8837)
Mean (95% CI) Median (Q1–Q3) Mean (95% CI) Median (Q1–Q3)
Total inpatient costs 1766 (1706 to 1826) 0 (0–2724) 4222 (4133 to 4311) 3400 (513–6754) −2454 (p<0.001)
Total outpatient costs 1314 (1291 to 1337) 1243 (449–1829) 476 (461 to 492) 251 (11–647) 838 (p<0.001)
Total costs 3081 (3025 to 3136) 2055 (1305–4227) 4698 (4610 to 4787) 3996 (1077–7124) −1617 (p<0.001)
All costs expressed in 2017 euros. Costs were calculated using data on all reimbursed medical care costs and rounded. Total inpatient costs 
included all specific intervention and medication costs in the hospital. Total outpatient costs included all specific intervention and medication 
costs outside the hospital.
Q1–Q3 , IQR range. 
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home care support received more appropriate and less 
inappropriate care at the end of life and had lower total 
medical care costs in the last 2 weeks of life, compared with 
those who did not use palliative home care support. More 
than four times as many people using palliative home 
care support died at home than those not using palliative 
home care support. Fewer people in the exposed cohort 
were admitted to the hospital, ED or ICU, and fewer 
people underwent diagnostic testing, blood transfusion, 
or surgery in the last 2 weeks of life.
Our study found that the use of palliative home care 
support lowered the average total medical care costs per 
person in the last 2 weeks of life by €1617. Costs of palli-
ative home care support use that was continued in the 
last 2 weeks of life are also taken into account. A litera-
ture review on costs of palliative care interventions in all 
settings between 2002 and 2011 also found that pallia-
tive care (including but not confined to palliative home 
care) was overall less costly than for comparator groups, 
despite large differences in the settings and study designs 
of the observed studies.27 However, the review notes that 
randomisation is absent in most of the studies, high-
lighting the importance of controlling for confounding 
factors and selection bias when analysing the impact of a 
palliative care intervention. Our study design could to a 
large extent tackle these issues of confounding and bias. 
A retrospective study using observational data evaluated 
the impact of a home-based palliative care programme 
in Southern California on costs in four disease groups 
and found that participants had in the last 6 months of 
life monthly net savings of $4258 for cancer, $4017 for 
chronic obstructive pulmonary disease, $3447 for heart 
failure and $2690 for dementia.21 Although generalising 
and comparing costs across different healthcare jurisdic-
tions is difficult due to differences in healthcare regula-
tions and reimbursement schemes, these numbers are in 
line with our findings.
 Our finding that people who used palliative home care 
support more often died at home confirms findings in 
previous studies.13 17 28–30 In Belgium, a mortality follow-
back study on a sample of 1.690 non-sudden deaths found 
that the involvement of a multidisciplinary palliative home 
care team was strongly associated with home death.30 
The rate of home deaths in the exposed and unexposed 
groups of our study, respectively 56.2% and 13.8%, was 
comparable with findings from an Italian study that 
compared the home death rates between users of pallia-
tive home care versus non-users (respectively 60.8% and 
29.3%). Although we were not able to take into account 
individual preferences on place of death and quality of 
death itself,31 our results show that the palliative home 
care support was effective in increasing the chance for 
home deaths on a population level, which is an important 
policy goal.32
Additionally, our study found that the use of palliative 
home care support has an impact on reducing hospital, 
ED and intensive care unit admissions in the last 2 weeks 
of life. This finding is in line with previous research,17 20 33 
but our study is the first to confirm such findings on a 
complete population level.
Strikingly, only 14% of all home-dwelling adults who 
died in Belgium in 2012 used palliative home care support 
in the last 2 years of life. This uptake is far below the 
actual need in the Belgian population for palliative care, 
which the most conservative estimation has set at 40% 
need in the population.4 Currently, physicians in Belgium 
can grant patients an official ‘palliative home care status’ 
only when the estimated life expectancy is 3 months or 
less. Although this status does not exclude the patient 
from receiving specific types of healthcare, such as in the 
hospice benefit system in the USA, the life expectancy 
criterion possibly discourages physicians from offering 
palliative home care support, especially in younger and 
non-cancer patients, and removing it could increase the 
use and timely initiation of palliative home care support. 
Further research should also be done to investigate the 
implications of accessing support at a different period in 
the disease trajectory on the quality and costs of care at 
the end of life.
strengths and limitations
An important strength of this study is that, by using 
nationwide administrative data on every death over one 
whole year, our findings are generalisable to the full 
population, whereas experimental studies, surveys or 
sample-based observational studies often have difficulties 
in reaching certain under-represented subgroups and 
lack the strength necessary for generalisability.3 Second, 
we used a previously validated set of QIs specifically devel-
oped to evaluate end-of-life care on a population level.25 
This allows comparing appropriateness of end-of-life care 
between different populations, both nationally and inter-
nationally. This approach is particularly useful for those 
parts of the healthcare sector that do not deliver direct 
individual patient care, such as health service researchers, 
public health and other policy makers.34 Our operation-
alisation of palliative home care support as the use of any 
of available supportive measures increases the reproduc-
ibility of our study in other countries and allows compar-
ison studies that focus on the impact of other existing 
types of palliative home care support. Other countries 
that have palliative home care support measures can use 
the same methodology to measure the impact of their 
measures on the quality and costs of end-of-life care. Addi-
tionally, countries that have no or other palliative home 
care support measures can use our results to research 
the possibility to implement such measures in their own 
healthcare system. It should be noted however that the 
generalisability of the results remains largely limited to 
countries or regions with similar healthcare delivery and 
funding systems.
Another strength of using administrative data is that, 
compared with other data collections methods, it is 
relatively inexpensive to collect data for a large popula-
tion without causing any burden to potentially vulner-
able people.35 In Belgium—where health insurance is 
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obligatory—administrative health claims data provide 
information on 99% of the population’s healthcare use. 
Moreover, propensity score matching as a causal infer-
ence technique for treatment effect estimation in large 
observational studies is a particularly useful method 
when a traditional randomised controlled trial design is 
not feasible nor ethical, as is the case for our research 
questions.16
Our study also has limitations. Even though our 
matched cohort study allows to cancel out several sources 
of confounding, it does not account for unmeasured 
covariates, such as patients’ or caregivers’ personality 
features, knowledge of and preferences with regard to the 
end of life, which can influence both home palliative care 
support use and the outcomes we evaluated. It cannot be 
ruled out, therefore, that the strong association between 
palliative home care use and the characteristics of end-of-
life care reflect underlying choices by patients, caregivers 
and family that impact both. For instance, to receive the 
palliative home care support in our study, patients should 
have a wish to die at home, which has been found to be an 
important predictor for actual home death.28 However, 
even if it would be that patients needed a certain knowl-
edge, attitude or mental switch to use palliative care, our 
results show that in these groups, quality of life increases 
and cost decreases. Although the circumstances of palli-
ative care decisions clearly warrant further investigation, 
as they are still only partially understood, our findings 
are relevant information for policy makers to convince 
people of the added value of palliative care.
The use of retrospective data also has limitations. 
Because palliative home care support is in reality often 
used relatively late in the disease trajectory, we chose to 
restrict the outcome measurement period to the last 14 
days of life to restrict the number of persons excluded 
from the intervention group. An additional limitation 
of using administrative data is that important aspects of 
quality end-of-life care that are not reimbursed, such as 
communication, existential or psychological care, are not 
visible. The QIs are not meant to serve as indicators for 
(in)appropriate care at the level of the individual patient, 
because clinical factors that justify an intervention and 
personal preferences can vary widely across patients. 
However, they are deemed valid at a population level. 
Our findings should be interpreted as an evaluation of 
the supportive policy measures for palliative home care 
on the aggregated level.
COnClusIOn
Palliative home care is an important part of end-of-life 
care. Those who want to be cared for at home and want to 
die at home have the right to use support to receive appro-
priate home care at the end of life. The findings from 
our nationwide retrospective matched cohort study show 
the positive impact of palliative home care support on 
the quality of end-of-life care. Additionally, we found that 
while the total costs for home care is higher, the average 
total reimbursed costs of medical care at the end of life 
is significantly lower for those who used palliative home 
care support. Our findings based on complete popula-
tion national data add important scientific evidence of 
the positive impacts palliative home care support has on 
the appropriateness of end-of-life care and on reducing 
societal costs related to care at the end of life. Because 
palliative home care support appears widely underused, 
our results suggest that increasing its availability and 
stimulating its use, therefore, has a potential to improve 
the appropriateness of care at the end of life of patients 
and at the same time reduce the expenses for the health 
insurer.
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